Patents by Inventor Peter G. Schultz

Peter G. Schultz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250127755
    Abstract: Disclosed herein are methods for using an antimalarial endoperoxide compound, such as artemisinin, in treating a subject suffering from myelodysplastic syndromes (MDS), and hi slowing or preventing the progression of MDS in the subject to development of acute myeloid leukemia (AML).
    Type: Application
    Filed: May 16, 2022
    Publication date: April 24, 2025
    Inventors: Daniel Kremer, Sida Shao, Peter G. Schultz, Michael J. Bollong
  • Patent number: 12275771
    Abstract: Disclosed herein are relaxin immunoglobulin fusion proteins useful for the treatment or prevention of a disease or condition in a subject.
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: April 15, 2025
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Feng Wang, Yan Liu, Ying Wang, Guangsen Fu, Peter G. Schultz
  • Patent number: 12269869
    Abstract: The present disclosure provides compositions, methods, kits, and platforms for selectively activating and deactivating chimeric receptor effector cells using humanized chimeric receptor effector cell switches that comprise a humanized targeting moiety that binds CD19 on a target cell and a chimeric receptor interacting domain that binds to a chimeric receptor effector cell and/or chimeric receptor effector cell switches comprising optimized chimeric receptor interacting domains. Also disclosed are methods of treating disease and conditions with such chimeric receptor effector cells and chimeric receptor effector cell switches.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: April 8, 2025
    Assignee: The Scripps Research Institute
    Inventors: Travis S. Young, Leonard Presta, David Rodgers, Eric Hampton, Timothy Wright, Peter G. Schultz, Eduardo Laborda, Elvira Khialeeva, Sophie Viaud
  • Patent number: 12263165
    Abstract: The present disclosure provides compounds, their pharmaceutical compositions, and methods of their use for treating mesenchymally-derived or mesenchymally-transformed cancers, such as breast cancers and sarcomas, and for treating diseases or disorders that are characterized by the expression of vimentin.
    Type: Grant
    Filed: July 11, 2023
    Date of Patent: April 1, 2025
    Assignees: The Scripps Research Institute, Board of Regents, The University of Texas System
    Inventors: Luke L. Lairson, Michael J. Bollong, Peter G. Schultz, Sendurai A. Mani
  • Patent number: 12252534
    Abstract: The present invention provides for humanized anti-CD3 antibodies and conjugates thereof. These conjugates may be useful in the treatment of conditions such as prostate cancer.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: March 18, 2025
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Chanhyuk Kim, Travis Young, Minsoo Kim, Jennifer Ma, Leonard Presta, Peter G. Schultz
  • Publication number: 20240207363
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.
    Type: Application
    Filed: November 20, 2023
    Publication date: June 27, 2024
    Inventors: Weijun SHEN, Pengyu YANG, Huafei ZOU, Peter G. SCHULTZ
  • Publication number: 20240174675
    Abstract: The present disclosure relates to compounds, and to their pharmaceutical compositions, that inhibit dipeptidyl peptidase IV (DPP4). The compounds selectively promote the proliferation of alveolar type 2 cells (AEC2s) and are useful in therapeutic methods of treating diseases whose etiology, for example, derives from epithelial degeneration and maladaptive remodeling, such as pulmonary diseases like idiopathic pulmonary fibrosis (IPF), acute respiratory distress syndrome (ARDS), and infant respiratory distress syndromes (IRDS).
    Type: Application
    Filed: January 20, 2022
    Publication date: May 30, 2024
    Inventors: Michael J. Bollong, Peter G. Schultz, Sida Shao, Arnab Chatterjee, Jian Jeffrey Chen, Nan Zhang
  • Publication number: 20240148884
    Abstract: Provided herein are peptides and peptide conjugates comprising a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The peptides may be used for blood glucose management and treating conditions such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: August 7, 2023
    Publication date: May 9, 2024
    Inventors: Weijun SHEN, Zaid AMSO, Peter G. Schultz
  • Publication number: 20240148747
    Abstract: The present disclosure provides compounds, or their tautomers or pharmaceutically acceptable salts thereof, and their pharmaceutical compositions that can selectively activate Yes-associated protein 1 (YAP). YAP activators of the present disclosure are useful in therapies such as wound and organ repair including, for example, treatment of chronic ulcers.
    Type: Application
    Filed: February 11, 2022
    Publication date: May 9, 2024
    Inventors: Michael J. Bollong, Peter G. Schultz, Arnab Chatterjee, Weijun Shen, Elshan Nakath G. Ralalage, Edyta M. Grzelak, Pengyu Yang
  • Publication number: 20240115577
    Abstract: The present disclosure relates to compounds. and to their pharmaceutical compositions. that inhibit dipeptidyl peptidase IV (DPP4). Hie compounds selectively promote the proliferation of alveolar type 2 cells (AEC2s) and are useful in therapeutic methods of treating diseases whose etiology. for example. derives from epithelial degeneration and maladaptive remodeling, such as pulmonary' diseases like idiopathic pulmonary fibrosis (IFF), acute respiratory' distress syndrome (ARDS), and infant respiratory' distress syndromes (IRDS).
    Type: Application
    Filed: January 14, 2022
    Publication date: April 11, 2024
    Inventors: Michael J. Bollong, Peter G. Schultz, Sida Shao, Arnab Chatterjee, Jian Jeffrey Chen, Nan Zhang
  • Patent number: 11865160
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: January 9, 2024
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Weijun Shen, Pengyu Yang, Huafei Zou, Peter G. Schultz
  • Publication number: 20230365695
    Abstract: Disclosed herein are immunoglobulin fusion proteins comprising a first antibody region, a first therapeutic agent, and a first connecting peptide; wherein the first therapeutic agent is attached to the first antibody region by the connecting peptide; and wherein the connecting peptide does not comprise a region having beta strand secondary structure. The connecting peptide may comprise an extender peptide. The extender peptide may have an alpha helical secondary structure. The connecting peptide may comprise a linker peptide. The linker peptide may not comprise any secondary structure. Also disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject.
    Type: Application
    Filed: April 21, 2023
    Publication date: November 16, 2023
    Inventors: Feng WANG, Yong ZHANG, Yan LIU, Peter G. SCHULTZ
  • Publication number: 20230357253
    Abstract: Disclosed herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and their pharmaceutical compositions: The compounds are useful as agonists of Stimulator of Interferon Genes (STING), such as in a method of treating a tumor.
    Type: Application
    Filed: September 2, 2021
    Publication date: November 9, 2023
    Inventors: Hank Michael James Petrassi, Luke L. Lairson, Emily Chin, Peter G. Schultz, Chenguang Yu, Baiyuan Yang, Virginia Grant, Yongkai Li, Alexander Pacheco, Alan Chu, Kristen Johnson, Arnab K. Chatterjee
  • Publication number: 20230355728
    Abstract: Disclosed herein are chimeric antigen receptor effector cells (CAR-ECs) and CAR-EC switches. The switchable CAR-ECs are generally T cells. The one or more chimeric antigen receptors may recognize a peptidic antigen on the CAR-EC switch. The CAR-ECs and switches may be used for the treatment of a condition in a subject in need thereof.
    Type: Application
    Filed: November 17, 2022
    Publication date: November 9, 2023
    Inventors: Travis Young, Chanhyuk Kim, Peter G. Schultz
  • Publication number: 20230346820
    Abstract: Disclosed herein ar methods that are useful for treating a subject who has a pathogenic infection, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); reducing the likelihood of the subject from being infected by a pathogen; and for reducing the transmission of a pathogen from a subject to others. The methods utilize a compound disclosed in Table 1 or Table 4 herein, optionally in combination with an additional agent such as an anti-infective agent.
    Type: Application
    Filed: April 15, 2021
    Publication date: November 2, 2023
    Inventors: Malina A. BAKOWSKI, Nathan BEUTLER, Dennis R. BURTON, Arnab K. CHATTERJEE, Case W. MCNAMARA, Thomas F. ROGERS, Peter G. SCHULTZ, Karen WOLFF, Laura RIVA
  • Publication number: 20230346781
    Abstract: The present disclosure provides compounds, their pharmaceutical compositions, and methods of their use for treating mesenchymally-derived or mesenchymally-transformed cancers, such as breast cancers and sarcomas, and for treating diseases or disorders that are characterized by the expression of vimentin.
    Type: Application
    Filed: July 11, 2023
    Publication date: November 2, 2023
    Applicants: The Scripps Research Institute, Board of Regents, The University of Texas System
    Inventors: Luke L. LAIRSON, Michael J. BOLLONG, Peter G. SCHULTZ, Sendurai A. Mani
  • Patent number: 11759461
    Abstract: The present disclosure provides compounds, their pharmaceutical compositions, and methods of their use for treating mesenchymally-derived or mesenchymally transformed cancers, such as breast cancers and sarcomas, and for treating diseases or disorders that are characterized by the expression of vimentin.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: September 19, 2023
    Assignees: THE SCRIPPS RESEARCH INSTITUTE, THE UNIVERSTY OF TEXAS SYSTEM,BOARD OF REGENTS
    Inventors: Luke L. Lairson, Michael J. Bollong, Peter G. Schultz, Sendurai A. Mani
  • Patent number: 11701364
    Abstract: The invention provides compounds having STimulator of INterferon Genes (STING) agonistic bioactivity that can be used in the treatment of tumors in patients afflicted therewith. The compounds are of formula (I): as defined herein. Compounds for practice of a method of the invention can be delivered via oral delivery for systemic exposure, as well as delivered intratumorally. Antitumor therapy using a compound of formula (I) can further comprise administration of an effective dose of an immune-checkpoint targeting drug.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: July 18, 2023
    Assignee: The Scripps Research Institute
    Inventors: Luke L. Lairson, Emily Chin, Arnab K. Chatterjee, Manoj Kumar, Ana Maria Gamo Albero, Hank Michael James Petrassi, Peter G. Schultz, Chenguang Yu, Junko Tamiya, William Vernier, Anil Gupta, Ramkumar Modukuri
  • Publication number: 20230192844
    Abstract: The present invention provides for humanized anti-CD3 antibodies and conjugates thereof. These conjugates may be useful in the treatment of conditions such as prostate cancer.
    Type: Application
    Filed: February 3, 2017
    Publication date: June 22, 2023
    Inventors: Chanhyuk KIM, Travis YOUNG, Minsoo KIM, Jennifer MA, Leonard PRESTA, Peter G. SCHULTZ
  • Patent number: 11673959
    Abstract: Disclosed herein are immunoglobulin fusion proteins comprising a first antibody region, a first therapeutic agent, and a first connecting peptide; wherein the first therapeutic agent is attached to the first antibody region by the connecting peptide; and wherein the connecting peptide does not comprise a region having beta strand secondary structure. The connecting peptide may comprise an extender peptide. The extender peptide may have an alpha helical secondary structure. The connecting peptide may comprise a linker peptide. The linker peptide may not comprise any secondary structure. Also disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: June 13, 2023
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Feng Wang, Yong Zhang, Yan Liu, Peter G. Schultz